Castle Biosciences, Inc. - Common stock (NQ:CSTL)

39.34 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Price and Volume

Volume	0
Open	39.34
Bid (Size)	15.74 (200)
Ask (Size)	62.94 (200)
Prev. Close	39.34
Today's Range	39.34 - 39.34
52wk Range	14.59 - 42.17
Shares Outstanding	25,167,365
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

January 11, 2026

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 19, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Performance

YTD	+2.1%	+2.1%
1 Month	+1.8%	+1.8%
3 Month	+72.5%	+72.5%
6 Month	+101.7%	+101.7%
1 Year	+50.4%	+50.4%

More News

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

December 17, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

December 12, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

December 09, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

November 17, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

November 14, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

November 11, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Why Castle Biosciences' Rally Might Just Be Getting Started ↗

November 05, 2025

Via Benzinga

AMD To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

November 05, 2025

Via Benzinga

Castle Biosciences Reports Third Quarter 2025 Results

November 03, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

November 03, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

A Glimpse of Castle Biosciences's Earnings Potential ↗

October 31, 2025

Via Benzinga

Castle Biosciences to Participate in Upcoming Investor Conferences

October 28, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

October 26, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

October 24, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

October 13, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

October 01, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

September 23, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025

September 17, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

September 09, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

August 25, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences to Participate in Upcoming Investor Conferences

August 21, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Here are the top movers in Tuesday's session. ↗

August 05, 2025

Via Chartmill

Frequently Asked Questions

Is Castle Biosciences, Inc. - Common stock publicly traded?

Yes, Castle Biosciences, Inc. - Common stock is publicly traded.

What exchange does Castle Biosciences, Inc. - Common stock trade on?

Castle Biosciences, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Castle Biosciences, Inc. - Common stock?

The ticker symbol for Castle Biosciences, Inc. - Common stock is CSTL on the Nasdaq Stock Market

What is the current price of Castle Biosciences, Inc. - Common stock?

The current price of Castle Biosciences, Inc. - Common stock is 39.34

When was Castle Biosciences, Inc. - Common stock last traded?

The last trade of Castle Biosciences, Inc. - Common stock was at 01/09/26 04:00 PM ET

What is the market capitalization of Castle Biosciences, Inc. - Common stock?

The market capitalization of Castle Biosciences, Inc. - Common stock is 990.08M

How many shares of Castle Biosciences, Inc. - Common stock are outstanding?

Castle Biosciences, Inc. - Common stock has 990M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.